Rapid Dose Therapeutics Corp. (RDTCF / CSE: DOSE) is a Canadian biotechnology and life sciences company centered on its QuickStrip™ oral thin-film drug delivery platform. The news flow around the company frequently combines product development updates with financing and corporate actions, giving investors insight into both its technology progress and its capital structure.
Readers of this news page can follow announcements on QuickStrip™-based initiatives, including nicotine-focused products such as QuickStrip™ Nicotine and NicStrip™, as well as harm reduction applications like the Replace+ sublingual cannabis strip developed with Eco Canadian Organic Inc. News releases have covered regulatory milestones such as a Health Canada submission for QuickStrip™ Nicotine in multiple dose strengths and details of a pharmacokinetic clinical study comparing nicotine absorption to combustible cigarettes.
In addition to product and partnership updates, Rapid Dose Therapeutics regularly reports on financing-related developments. These include private placement financings involving secured convertible notes and warrants, extensions of note maturities and warrant expiries, and the issuance of common shares to pay accrued interest on secured debt. The company has also disclosed shares-for-debt transactions with creditors and directors aimed at reducing outstanding liabilities.
By reviewing the news items linked on this page, investors and observers can track how Rapid Dose Therapeutics advances its QuickStrip™ technology across nicotine, cannabis, nutraceutical and pharmaceutical applications, while also monitoring share issuances, note terms and other corporate actions that affect its capital structure. This page is a central source for the company’s publicly released updates and disclosures.
Rapid Dose Therapeutics (CSE: DOSE) announced plans to issue common shares to satisfy the quarterly interest payment due June 30, 2025, on its secured convertible notes. The company will issue 506,878 common shares at $0.185 per share to settle $93,775.72 in accrued interest.
The notes, issued in 2023 through a private placement financing totaling $3,134,445, bear interest at 12.0% per annum and mature on November 30, 2025. The original financing units included both notes and warrants, with 15,672,225 warrants issued in total. The interest payment shares will be subject to a four-month hold period.
Rapid Dose Therapeutics (CSE: DOSE) has announced a shares-for-debt transaction to settle director fees. The company will issue common shares to its five non-management directors to cancel $100,000 in total fees owed for the fiscal quarters ended February 28, 2025, and May 31, 2025.
The shares will be issued at a deemed price of $0.21 per share, based on the closing price on June 27, 2025. The transaction, expected to complete by July 15, 2025, aims to improve the company's financial position by reducing liabilities. The issued shares will be subject to a four-month hold period.
Rapid Dose Therapeutics (RDTCF) has announced plans for an equity private placement financing to raise up to $3 million in gross proceeds. The financing will offer up to 13,636,364 units at $0.22 per unit, with each unit comprising one common share and one warrant. The warrants will be exercisable at $0.34 per share for a two-year term.
Meadowbank Asset Management will serve as the agent, receiving a 6% cash commission and 6% in agent warrants from investors they introduce. The proceeds will be used for research and development, capital expansion, and working capital. The securities will have a four-month hold period from closing.
["Potential to raise up to $3 million in additional capital", "Proceeds will support R&D, capital expansion, and working capital needs", "Two-year warrant term provides flexibility for investors"]Rapid Dose Therapeutics (RDTCF) and Aavishkar Oral Strips have filed two crucial patent applications for innovative nicotine delivery technology. The patents cover both dissolvable and non-dissolvable oral nicotine strips using RDT's QuickStrip™ platform. The dissolvable variant enables nicotine delivery in under 2 minutes, while the non-dissolvable version offers extended release in a slim format.
The international PCT applications filed with WIPO extend protection to 158 jurisdictions worldwide. This development follows a pre-commercialization agreement with a leading global tobacco company announced in January 2025. The technology aims to provide a safer alternative for the 1.3 billion global tobacco users, targeting the 60% of smokers wanting to quit.
Rapid Dose Therapeutics (RDTCF) has announced a debt settlement agreement with certain creditors. The company plans to issue up to 2.5 million common shares in exchange for canceling approximately $500,000 in outstanding accounts payable. The Settlement Shares will be issued at $0.20 per share.
The transaction aims to improve RDT's financial position by reducing existing liabilities. Settlement Shares issued to Canadian residents will have a four-month hold period. The agreement requires Canadian Securities Exchange approval and will not create a new control person of the company.
Rapid Dose Therapeutics (RDTCF) has provided an update on its collaboration with the University of Regina's Faculty of Kinesiology & Health Studies for an NFL-funded medical cannabis research project. The study focuses on examining cannabinoids' effects on sport concussion and pain management.
The project has entered the clinical trial phase, investigating the bioavailability of CBD through RDT's QuickStrip™ sublingual delivery system compared to standard oral formulation. The randomized, two-arm clinical study, approved by Health Canada, involves researchers from the Universities of Regina, Saskatchewan, and British Columbia.
The study specifically examines the pharmacokinetic parameters of non-psychoactive cannabidiol (CBD) and its metabolites in healthy young adults. The QuickStrip™ technology consists of rectangular oral thin films infused with cannabis extract that dissolve under the tongue, releasing the compound directly into the mucus membranes.
Rapid Dose Therapeutics (CSE: DOSE) has announced its participation in major dental tradeshows across Canada to showcase XyliStrip, an oral dissolving thin film strip powered by QuickStrip technology. The product is designed to address dry mouth (Xerostomia), which affects over 20% of the population and is one of North America's fastest-growing oral health problems.
XyliStrip utilizes RDT's proprietary sublingual thin film strip technology that can be infused with various active ingredients, including Nutraceuticals, Pharmaceuticals, Cannabis, and Nicotine, for rapid bloodstream delivery. The company will present at seven major dental events from April to October 2025, including the Women In Dentistry Symposium, Ontario Society of Periodontists Spring Meeting, and the American Association of Periodontology & Canadian Association of Periodontists Joint Meeting.
Rapid Dose Therapeutics (CSE: DOSE) has announced plans to issue common shares to satisfy the quarterly interest payment due March 31, 2025, on its secured convertible notes. The company will issue 463,716 common shares at $0.20 per share, totaling $92,745.22 in accrued interest.
The notes, issued in 2023 through a private placement financing of $3,134,445, carry a 12% annual interest rate and mature on November 30, 2025. The financing included units priced at $1.00, each comprising notes and five common share purchase warrants, resulting in 15,672,225 warrants issued.
Additionally, RDT has received an extension from the CSE until April 24, 2025, to complete its previously announced shares-for-debt transaction. This transaction involves issuing up to 1,600,000 common shares at $0.25 per share to settle approximately $400,000 in outstanding accounts payable with creditors.
Rapid Dose Therapeutics Corp (CSE: DOSE) has announced plans for an equity private placement financing to raise up to $5,000,000 in gross proceeds. The financing will consist of up to 20,833,333 common shares priced at $0.24 per share.
The company has engaged Meadowbank Asset Management Inc. as the agent, who will receive a 1% cash commission on proceeds from investors they introduce, plus agent warrants equal to 6% of shares issued to their referred investors. Each agent warrant will be exercisable at $0.33 per share for two years.
The proceeds will be used for debt retirement, research and development, capital expansion, and working capital. The financing may close in multiple tranches, with securities subject to a four-month hold period.